Idorsia’s Quviviq (daridorexant) Receives NICE Recommendation for Adults with Chronic Insomnia
Shots:
- NICE has issued final draft guidance recommending Quviviq for use in England and Wales to treat insomnia in adults with symptoms lasting three nights or more in a week for at least 3mos. with daytime functioning impairment
- The 2 P-III studies evaluating the efficacy and safety of daridorexant in patients with insomnia disorder demonstrated that daridorexant improved sleep onset, sleep maintenance, sTST, and daytime sleepiness at the recommended dose in adults with insomnia disorder at 1 & 3mos. over PBO
- Quviviq received marketing authorization from the MHRA in Great Britain in Aug 2022 for the treatment of adult patients with insomnia & also received marketing authorization in Canada in May 2023
Ref: PR Newswire | Image: Idorsia
Related News:- Idorsia Reports the Commercial Availability of Quviviq (daridorexant) in Switzerland for Chronic Insomnia Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
